AXA decreased its holdings in shares of Jazz Pharmaceuticals plc – (NASDAQ:JAZZ) by 24.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 87,969 shares of the specialty pharmaceutical company’s stock after selling 28,893 shares during the period. AXA owned about 0.15% of Jazz Pharmaceuticals worth $11,845,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Several other large investors have also made changes to their positions in JAZZ. Dynamic Technology Lab Private Ltd purchased a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $296,000. Boston Partners purchased a new position in Jazz Pharmaceuticals in the 4th quarter valued at $161,470,000. LSV Asset Management lifted its holdings in Jazz Pharmaceuticals by 20.1% in the 4th quarter. LSV Asset Management now owns 159,570 shares of the specialty pharmaceutical company’s stock valued at $21,486,000 after purchasing an additional 26,740 shares in the last quarter. Schroder Investment Management Group purchased a new position in Jazz Pharmaceuticals in the 3rd quarter valued at $52,571,000. Finally, Orbimed Advisors LLC lifted its holdings in Jazz Pharmaceuticals by 16.0% in the 3rd quarter. Orbimed Advisors LLC now owns 749,200 shares of the specialty pharmaceutical company’s stock valued at $109,571,000 after purchasing an additional 103,300 shares in the last quarter. Hedge funds and other institutional investors own 91.20% of the company’s stock.
JAZZ has been the topic of a number of research reports. Wells Fargo restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Monday, December 25th. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $128.58 to $163.75 in a report on Monday, March 19th. Cantor Fitzgerald restated a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Sunday, December 3rd. Zacks Investment Research lowered Jazz Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, January 2nd. Finally, BMO Capital Markets raised their price objective on Jazz Pharmaceuticals from $196.00 to $199.00 and gave the company an “outperform” rating in a report on Wednesday, February 28th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and seventeen have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $181.04.
Shares of NASDAQ:JAZZ traded down $4.66 during midday trading on Monday, reaching $146.33. 378,307 shares of the company’s stock were exchanged, compared to its average volume of 439,860. The company has a current ratio of 3.29, a quick ratio of 3.15 and a debt-to-equity ratio of 0.57. The company has a market capitalization of $9,029.72, a price-to-earnings ratio of 15.31, a PEG ratio of 0.79 and a beta of 0.97. Jazz Pharmaceuticals plc – has a fifty-two week low of $128.58 and a fifty-two week high of $163.75.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 27th. The specialty pharmaceutical company reported $2.58 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.73 by ($0.15). The business had revenue of $436.40 million for the quarter, compared to analyst estimates of $440.91 million. Jazz Pharmaceuticals had a return on equity of 22.63% and a net margin of 30.14%. equities research analysts predict that Jazz Pharmaceuticals plc – will post 11.48 earnings per share for the current fiscal year.
In related news, SVP Paul Treacy sold 877 shares of the firm’s stock in a transaction dated Friday, March 2nd. The stock was sold at an average price of $139.62, for a total transaction of $122,446.74. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Michael Patrick Miller sold 200 shares of the firm’s stock in a transaction dated Friday, January 12th. The stock was sold at an average price of $148.65, for a total value of $29,730.00. Following the sale, the executive vice president now directly owns 21,669 shares of the company’s stock, valued at $3,221,096.85. The disclosure for this sale can be found here. Insiders have sold a total of 12,758 shares of company stock valued at $1,881,171 over the last three months. Corporate insiders own 4.30% of the company’s stock.
Jazz Pharmaceuticals Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.